1. Home
  2. BIIB vs PHG Comparison

BIIB vs PHG Comparison

Compare BIIB & PHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BIIB
  • PHG
  • Stock Information
  • Founded
  • BIIB 1978
  • PHG 1891
  • Country
  • BIIB United States
  • PHG Netherlands
  • Employees
  • BIIB N/A
  • PHG N/A
  • Industry
  • BIIB Biotechnology: Pharmaceutical Preparations
  • PHG Medical Electronics
  • Sector
  • BIIB Health Care
  • PHG Health Care
  • Exchange
  • BIIB Nasdaq
  • PHG Nasdaq
  • Market Cap
  • BIIB 25.1B
  • PHG 24.6B
  • IPO Year
  • BIIB 1991
  • PHG N/A
  • Fundamental
  • Price
  • BIIB $159.26
  • PHG $26.24
  • Analyst Decision
  • BIIB Buy
  • PHG Hold
  • Analyst Count
  • BIIB 25
  • PHG 4
  • Target Price
  • BIIB $258.57
  • PHG N/A
  • AVG Volume (30 Days)
  • BIIB 1.6M
  • PHG 594.9K
  • Earning Date
  • BIIB 10-30-2024
  • PHG 02-03-2025
  • Dividend Yield
  • BIIB N/A
  • PHG N/A
  • EPS Growth
  • BIIB 10.05
  • PHG N/A
  • EPS
  • BIIB 11.06
  • PHG N/A
  • Revenue
  • BIIB $9,607,500,000.00
  • PHG $20,119,339,720.00
  • Revenue This Year
  • BIIB N/A
  • PHG $3.01
  • Revenue Next Year
  • BIIB N/A
  • PHG $4.34
  • P/E Ratio
  • BIIB $14.41
  • PHG N/A
  • Revenue Growth
  • BIIB N/A
  • PHG N/A
  • 52 Week Low
  • BIIB $153.62
  • PHG $19.55
  • 52 Week High
  • BIIB $268.30
  • PHG $32.91
  • Technical
  • Relative Strength Index (RSI)
  • BIIB 35.47
  • PHG 38.60
  • Support Level
  • BIIB $158.44
  • PHG $26.81
  • Resistance Level
  • BIIB $165.29
  • PHG $27.28
  • Average True Range (ATR)
  • BIIB 3.42
  • PHG 0.29
  • MACD
  • BIIB 1.04
  • PHG 0.16
  • Stochastic Oscillator
  • BIIB 44.34
  • PHG 40.23

About BIIB Biogen Inc.

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

About PHG Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. Nearly 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, and image-guided therapy solutions. The connected care segment (around 30% of revenue) encompasses monitoring and analytics systems for hospitals, informatics business, and also houses the sleep and respiratory care segment. Personal health business (remainder of revenue) is mainly oral health and personal care product lines, which include electric toothbrushes and men's grooming and personal care products.

Share on Social Networks: